Pharmaceutical giant Bayer filed an appeal against the granting
of a compulsory licence for Nexavar to Indian generic manufacturer
Natco, but in March the IPAB dismissed the appeal, as R.
Muralidharan and Ashima Katara report.
In a landmark ruling in one of the world's fastest growing
pharmaceutical markets, the Intellectual Property Appellate Board
(IPAB) of India upheld the compulsory licence granted to Natco
Pharma Limited, an Indian drug manufacturer, for Bayer AG's
Nexavar (sorafenib tosylate), an oncology palliative drug.
Natco approached Bayer for a voluntary licence which was
refused. Natco then went ahead to file a compulsory licence
application before the Controller of Patents on the grounds that
the patentee had not worked the patent in India and the drug in
question was being imported by the patentee even three years after
the grant of patent; that the cost of Bayer's patented drug was
Rs280,000 ($5,000) per month and because of the high cost,